192 related articles for article (PubMed ID: 32944771)
1. Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy.
Workum JD; Kramers C; Kolwijck E; Schouten JA; de Wildt SN; Brüggemann RJ
J Antimicrob Chemother; 2021 Jan; 76(1):212-219. PubMed ID: 32944771
[TBL] [Abstract][Full Text] [Related]
2. Nephrotoxicity of teicoplanin-based combination therapy: focus on piperacillin/tazobactam and other anti-pseudomonal β-lactams.
Tai CH; Shao CH; Wang CC; Lin FJ; Wang JT; Wu CC
J Antimicrob Chemother; 2021 Jan; 76(2):499-506. PubMed ID: 33152760
[TBL] [Abstract][Full Text] [Related]
3. Incidence of acute kidney injury after teicoplanin- or vancomycin- and piperacillin/tazobactam combination therapy: A comparative study using propensity score matching analysis.
Sazanami K; Inose R; Yagi T; Dote S; Horiuchi N; Kobayashi Y; Muraki Y
J Infect Chemother; 2021 Dec; 27(12):1723-1728. PubMed ID: 34446352
[TBL] [Abstract][Full Text] [Related]
4. Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children.
Downes KJ; Cowden C; Laskin BL; Huang YS; Gong W; Bryan M; Fisher BT; Goldstein SL; Zaoutis TE
JAMA Pediatr; 2017 Dec; 171(12):e173219. PubMed ID: 28973124
[TBL] [Abstract][Full Text] [Related]
5. Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity score-matched study.
Buckley MS; Komerdelj IA; D'Alessio PA; Rangan P; Agarwal SK; Tinta NC; Martinez BK; Ziadat DS; Yerondopoulos MJ; Kobic E; Kane-Gill SL
J Crit Care; 2022 Feb; 67():134-140. PubMed ID: 34768175
[TBL] [Abstract][Full Text] [Related]
6. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.
Hammond DA; Smith MN; Painter JT; Meena NK; Lusardi K
Pharmacotherapy; 2016 May; 36(5):463-71. PubMed ID: 26952639
[TBL] [Abstract][Full Text] [Related]
7. Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime.
Navalkele B; Pogue JM; Karino S; Nishan B; Salim M; Solanki S; Pervaiz A; Tashtoush N; Shaikh H; Koppula S; Koons J; Hussain T; Perry W; Evans R; Martin ET; Mynatt RP; Murray KP; Rybak MJ; Kaye KS
Clin Infect Dis; 2017 Jan; 64(2):116-123. PubMed ID: 27986669
[TBL] [Abstract][Full Text] [Related]
8. Comparison of teicoplanin versus vancomycin in combination with piperacillin-tazobactam or meropenem for the risk of acute kidney injury.
Aslan AT; Pashayev T; Dağ O; Akova M
Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1953-1961. PubMed ID: 33884515
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam.
Burgess LD; Drew RH
Pharmacotherapy; 2014 Jul; 34(7):670-6. PubMed ID: 24855041
[TBL] [Abstract][Full Text] [Related]
10. Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study.
Miano TA; Hennessy S; Yang W; Dunn TG; Weisman AR; Oniyide O; Agyekum RS; Turner AP; Ittner CAG; Anderson BJ; Wilson FP; Townsend R; Reilly JP; Giannini HM; Cosgriff CV; Jones TK; Meyer NJ; Shashaty MGS
Intensive Care Med; 2022 Sep; 48(9):1144-1155. PubMed ID: 35833959
[TBL] [Abstract][Full Text] [Related]
11. The concomitant use of vancomycin and piperacillin-tazobactam is associated with acute kidney injury (AKI) in extremely low birth weight infants (ELBW).
Al-Jebawi Y; Karalic K; Shekhawat P; Mhanna MJ
J Neonatal Perinatal Med; 2022; 15(2):303-309. PubMed ID: 34864693
[TBL] [Abstract][Full Text] [Related]
12. Incidence and Risk Factors of Acute Kidney Injury in Patients Receiving Concomitant Vancomycin and Continuous-Infusion Piperacillin/Tazobactam: A Retrospective Cohort Study.
Blair K; Covington EW
Ann Pharmacother; 2020 Nov; 54(11):1096-1101. PubMed ID: 32406243
[TBL] [Abstract][Full Text] [Related]
13. Effect of concomitant vancomycin and piperacillin-tazobactam on frequency of acute kidney injury in pediatric patients.
Buhlinger KM; Fuller KA; Faircloth CB; Wallace JR
Am J Health Syst Pharm; 2019 Aug; 76(16):1204-1210. PubMed ID: 31369115
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for acute kidney injury in vancomycin and piperacillin/tazobactam combination therapy: A retrospective study.
Yamashita Y; Kawaguchi H; Yano T; Sakurai N; Shibata W; Oshima K; Imai T; Yamada K; Nakamura Y; Nagayama K; Kakeya H
J Infect Chemother; 2021 Nov; 27(11):1614-1620. PubMed ID: 34366231
[TBL] [Abstract][Full Text] [Related]
15. Comparative incidence and excess risk of acute kidney injury in hospitalised patients receiving vancomycin and piperacillin/tazobactam in combination or as monotherapy.
Carreno J; Smiraglia T; Hunter C; Tobin E; Lomaestro B
Int J Antimicrob Agents; 2018 Nov; 52(5):643-650. PubMed ID: 30103003
[TBL] [Abstract][Full Text] [Related]
16. Retrospective Cohort Study of the Incidence of Acute Kidney Injury with Vancomycin Area under the Curve-Based Dosing with Concomitant Piperacillin-Tazobactam Compared to Meropenem or Cefepime.
Kiley PS; Pearston AP; Hodge LA; Kaplan MC; Baczek SM; Stanley JS; Wilson TJ; Soriano KM; Yao A; Shaeffer ZA; Talt IE; Cohen JA; Ingemi AI
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0004022. PubMed ID: 35867523
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial Stewardship.
Karino S; Kaye KS; Navalkele B; Nishan B; Salim M; Solanki S; Pervaiz A; Tashtoush N; Shaikh H; Koppula S; Martin ET; Mynatt RP; Murray KP; Rybak MJ; Pogue JM
Antimicrob Agents Chemother; 2016 Jun; 60(6):3743-50. PubMed ID: 27067325
[TBL] [Abstract][Full Text] [Related]
18. Co-administration of vancomycin and piperacillin-tazobactam is associated with increased renal dysfunction in adult and pediatric burn patients.
Hundeshagen G; Herndon DN; Capek KD; Branski LK; Voigt CD; Killion EA; Cambiaso-Daniel J; Sljivich M; De Crescenzo A; Mlcak RP; Kinsky MP; Finnerty CC; Norbury WB
Crit Care; 2017 Dec; 21(1):318. PubMed ID: 29262848
[TBL] [Abstract][Full Text] [Related]
19. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime.
Gomes DM; Smotherman C; Birch A; Dupree L; Della Vecchia BJ; Kraemer DF; Jankowski CA
Pharmacotherapy; 2014 Jul; 34(7):662-9. PubMed ID: 24753221
[TBL] [Abstract][Full Text] [Related]
20. Acute kidney injury risk associated with piperacillin/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function.
Jeon N; Staley B; Klinker KP; Hincapie Castillo J; Winterstein AG
Int J Antimicrob Agents; 2017 Jul; 50(1):63-67. PubMed ID: 28522340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]